162 related articles for article (PubMed ID: 32527950)
21. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
[TBL] [Abstract][Full Text] [Related]
22. Stromal Cell PD-L1 Inhibits CD8
O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
[TBL] [Abstract][Full Text] [Related]
23. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
24. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
25. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
26. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
[TBL] [Abstract][Full Text] [Related]
27. Human CD8
Machicote A; Belén S; Baz P; Billordo LA; Fainboim L
Front Immunol; 2018; 9():2788. PubMed ID: 30555473
[TBL] [Abstract][Full Text] [Related]
28. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
30. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
31. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.
Kaiser AD; Schuster K; Gadiot J; Borkner L; Daebritz H; Schmitt C; Andreesen R; Blank C
Eur J Immunol; 2012 Mar; 42(3):662-71. PubMed ID: 22144176
[TBL] [Abstract][Full Text] [Related]
32. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
[TBL] [Abstract][Full Text] [Related]
33. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
35. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
36. Evodiamine suppresses non-small cell lung cancer by elevating CD8
Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
[TBL] [Abstract][Full Text] [Related]
37. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.
Park HJ; Park JS; Jeong YH; Son J; Ban YH; Lee BH; Chen L; Chang J; Chung DH; Choi I; Ha SJ
J Immunol; 2015 Jun; 194(12):5801-11. PubMed ID: 25934860
[TBL] [Abstract][Full Text] [Related]
38. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
39. Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8
Li Q; Wei S; Li Y; Wu F; Qin X; Li Z; Li J; Chen C
Inflamm Res; 2023 Apr; 72(4):783-796. PubMed ID: 36867228
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis.
Carambia A; Gottwick C; Schwinge D; Stein S; Digigow R; Şeleci M; Mungalpara D; Heine M; Schuran FA; Corban C; Lohse AW; Schramm C; Heeren J; Herkel J
Immunology; 2021 Apr; 162(4):452-463. PubMed ID: 33346377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
